促进神经发生作为治疗阿尔茨海默病的策略
Abena Dwamena1, Rashini Beragama-Arachchi1, Hongmin Wang1
1Department of Pharmacology and Neuroscience, Garrison Institute on Aging, Center of Excellence for Translational Neuroscience and Therapeutics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
International journal of molecular sciences
|September 27, 2025
概括
阿尔茨海默病会影响成年人的神经发生,也就是大脑产生新神经元的能力. 促进神经发生的再生疗法显示出恢复认知功能和补充当前阿尔茨海默氏症治疗的前景.
科学领域:
- 神经科学是一个神经科学.
- 再生医学是一种再生医学.
- 神经退行性疾病 神经退行性疾病
背景情况:
- 阿尔茨海默病 (AD) 的特点是渐进的认知衰退和神经元损失,与粉样β斑块和团有关.
- 目前针对核心病理的AD治疗方法在临床上取得了有限的成功,这引发了对再生策略的兴趣.
- 成年海马神经发生,从神经干细胞 (NSC) 生成新神经元,在AD中受损,加剧认知缺陷.
研究的目的:
- 审查调节成人神经发生的分子机制及其在阿尔茨海默病中的失调.
- 突出旨在增强AD治疗神经发生的治疗策略.
- 在临床前AD模型和临床试验中评估促进神经发生的疗法的潜力.
主要方法:
- 对控制成人神经发生的分子途径的审查 (转录性,表观遗传性,炎症性,代谢性).
- 检查这些途径是如何在阿尔茨海默病中改变的.
- 对AD神经发生增强疗法的临床前和临床数据的分析.
主要成果:
- 神经发生机制的失调有助于AD病理和认知衰退.
- 包括药理学药物,干细胞疗法,基因疗法和表观遗传调节在内的治疗策略显示出潜在的潜力.
- 临床前研究表明,增强神经发生能改善认知和减少AD相关的大脑病理.
结论:
- 促进成年人的神经生成代表了阿尔茨海默病的有希望的治疗途径.
- 这些再生方法可以通过恢复神经功能来补充现有的治疗方法.
- 在AD治疗中,需要对神经发生学重点治疗进行进一步的临床研究.
相关概念视频
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
Neurogenesis and Regeneration of Nervous Tissue
1.6K
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
1.6K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560


